Nektar Therapeutics (NKTR)

20.15
NASDAQ : Health Technology
Prev Close 20.22
Day Low/High 20.02 / 20.76
52 Wk Low/High 16.56 / 62.70
Avg Volume 2.65M
Exchange NASDAQ
Shares Outstanding 175.27M
Market Cap 3.54B
EPS 4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics

The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed against Nektar Therapeutics (NASDAQ: NKTR) ("Nektar") on behalf of those who purchased or otherwise acquired Nektar securities...

LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors To Contact The Firm

LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors To Contact The Firm

SAN DIEGO, Aug. 30, 2019 /PRNewswire/ -- Johnson Fistel, LLP announces that class action lawsuits have been commenced on behalf of shareholders of the publicly-traded companies listed below.

ROSEN, A TOP RANKED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

ROSEN, A TOP RANKED LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

NEW YORK, Aug. 29, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) from February 15, 2019 through August...

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Nektar Therapeutics

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Nektar Therapeutics

Law Offices of Howard G. Smith reminds investors of the upcoming October 18, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR)...

INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders Of Class Action And Lead Plaintiff Deadline: October 18, 2019

INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders Of Class Action And Lead Plaintiff Deadline: October 18, 2019

NEW YORK, Aug. 22, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar"  or the Company") (NASDAQ: NKTR) and certain of its...

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Nektar Therapeutics And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Nektar Therapeutics And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of...

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) from February 15, 2019 through August 8, 2019, inclusive (the "Class Period").

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Nektar Therapeutics Investors (NKTR)

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Nektar Therapeutics Investors (NKTR)

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) securities between February 15, 2019 and August 8, 2019, inclusive (the "Class Period").

Glancy Prongay & Murray LLP Files A Securities Class Action On Behalf Of Nektar Therapeutics Investors (NKTR)

Glancy Prongay & Murray LLP Files A Securities Class Action On Behalf Of Nektar Therapeutics Investors (NKTR)

Glancy Prongay & Murray LLP ("GPM") announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Damiba v.

Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Nektar Therapeutics (NKTR)

Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Nektar Therapeutics (NKTR)

NEW YORK, Aug. 14, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR).

Nektar Therapeutics Drops Sharply for Second Day After Admitting Batch Issues

Nektar Therapeutics Drops Sharply for Second Day After Admitting Batch Issues

Nektar dropped 40% on Friday after announcing it had manufacturing issues in two batches of experimental cancer drugs.

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Nektar Therapeutics And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Nektar Therapeutics And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities...

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Nektar Therapeutics Investors

Glancy Prongay & Murray LLP Announces Investigation On Behalf Of Nektar Therapeutics Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) investors concerning the Company and its officers' possible violations of federal securities laws.

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Nektar Therapeutics Investors

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Nektar Therapeutics Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) investors concerning the Company and its officers' possible violations of federal securities laws.

Investor Alert: Ademi & O'Reilly, LLP Investigates Possible Securities Fraud Of Nektar Therapeutics

Investor Alert: Ademi & O'Reilly, LLP Investigates Possible Securities Fraud Of Nektar Therapeutics

MILWAUKEE, Aug. 9, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating possible securities fraud claims against Nektar (Nasdaq: NKTR) resulting from inaccurate statements Nektar made regarding its business practices, financial statements and...

Nektar Therapeutics Sinks on Cancer Treatment Manufacturing Issues

Nektar Therapeutics Sinks on Cancer Treatment Manufacturing Issues

Nektar says there have been manufacturing issues in two batches of experimental cancer drugs.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CHUY, CNNE, CODI, CUB, GWRS, PLOW, SBRA, WK Downgrades: AC, AVT, CECO, GDOT, GMRE, HMLP, INVA, IONS, IVR, MPAA, MUFG, NKTR, PPIH, QDEL, TGE, TRUE, UVV, WES, WMGI Initiations: AVLR Read on to get TheStreet Quant Ratings' detailed report:

Nektar Therapeutics Reports Financial Results For The Second Quarter Of 2019

Nektar Therapeutics Reports Financial Results For The Second Quarter Of 2019

Company to Host Conference Call with Analysts to Review Financial Results and Provide Update on the NKTR-214 (bempegaldesleukin) Program

Nektar Therapeutics And Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation For Bempegaldesleukin (NKTR-214) In Combination With Opdivo® (nivolumab) For The Treatment Of Patients With Untreated Advanced Melanoma

Nektar Therapeutics And Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation For Bempegaldesleukin (NKTR-214) In Combination With Opdivo® (nivolumab) For The Treatment Of Patients With Untreated Advanced Melanoma

SAN FRANCISCO, Aug. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced that the U.

Nektar To Announce Financial Results For The Second Quarter 2019 On Thursday, August 8, 2019, After Close Of U.S.-Based Financial Markets

Nektar To Announce Financial Results For The Second Quarter 2019 On Thursday, August 8, 2019, After Close Of U.S.-Based Financial Markets

SAN FRANCISCO, July 30, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 8, 2019, after the close of U.

Big Trouble in Small Caps Chart?

If you want to fret over a long-term moving average line, then fret over the Russell 2000’s: The 50-day and the 200-day moving average lines are both heading down.

First-in-Human Data Presented From Phase 1a Study Of NKTR-358, A Novel T Regulatory Cell Stimulator, At Annual European Congress Of Rheumatology

First-in-Human Data Presented From Phase 1a Study Of NKTR-358, A Novel T Regulatory Cell Stimulator, At Annual European Congress Of Rheumatology

MADRID and SAN FRANCISCO, June 13, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator in...

Nektar Therapeutics To Host Webcast Conference Call With Immunology Expert For Analysts & Investors During 2019 European Congress Of Rheumatology (EULAR 2019)

Nektar Therapeutics To Host Webcast Conference Call With Immunology Expert For Analysts & Investors During 2019 European Congress Of Rheumatology (EULAR 2019)

SAN FRANCISCO, June 11, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with an immunology expert and company management on Thursday, June 13, 2019 at 8:00 a.

Nektar Therapeutics Jumps on Positive Results From Melanoma Treatment Study

Nektar Therapeutics Jumps on Positive Results From Melanoma Treatment Study

The company says the test revealed patients were experiencing 'deepening and durability of response over time' with the treatment.

Nektar Therapeutics Presents Biomarker And Clinical Data From PIVOT-02 Phase 2 Study Of Bempegaldesleukin With Nivolumab At 2019 ASCO Annual Meeting

Nektar Therapeutics Presents Biomarker And Clinical Data From PIVOT-02 Phase 2 Study Of Bempegaldesleukin With Nivolumab At 2019 ASCO Annual Meeting

CHICAGO, June 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that biomarker and clinical data from PIVOT-02 is being presented at the 2019 American Society of Clinical Oncology (ASCO) Meeting in Chicago, Illinois.

TheStreet Quant Rating: D (Sell)